Nadine Arnold Steffens

Ms. Nadine Arnold Steffens

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
Nadine Arnold SteffensNadine Arnold Steffens
Nadine Arnold Steffens
EZEstevan S. Zimmermann
Estevan S. Zimmermann
SNSabrina M. Nichelle
Sabrina M. Nichelle
NBNatalia Brucker
Natalia Brucker
What is known and objective Meropenem, a carbapenem antibiotic, is widely prescribed for the treatment of life‐threatening infections. The main parameter associated with its therapeutic success is the percentage of time that the levels remain above the minimum inhibitory concentration. Inadequate levels of meropenem can lead to therapeutic failure and increase the possibility of microbial resistance. The employment of strategies involving dose regimens and drug pharmacodynamics has become increasingly important to optimize therapies. In the present study, we conducted a review with the purpose of assembling information about the clinical use of meropenem and therapeutic drug monitoring. Methods A literature review emphasizing the application of therapeutic drug monitoring (TDM) of meropenem in clinical practice has been done. To identify articles related to the topic, we performed a standardized search from January 21, 2020 to December 21, 2020, using specific descriptors in PubMed, Lilacs and Embase. Results and discussion In total, 35 studies were included in the review. The daily dose of meropenem commonly ranged from 3 to 6 g/day. Critically ill patients and those with impaired renal function appear to be the most suitable patients for the application of meropenem TDM, in order to guide therapy. We observed that most of the studies recommend TDM and that, in nine locations, the TDM of meropenem and of other beta‐lactams is a routine practice. TDM data can help to maximize the clinical outcomes of the treatment with meropenem. It can also improve the patient care by providing suitable levels of meropenem, guiding the most appropriate dose regimens, which is the main parameter associated with therapeutic success. What is new and conclusion The findings from this review suggest that the therapeutic monitoring of meropenem can be beneficial, since it adjusts the treatment and aids clinical outcomes. It does so by indicating the appropriate dosage and preventing failure, toxicity and possible antimicrobial resistance. The multidisciplinary effort, basic knowledge and communication among the medical team are also essential.

25 November 2020 in Toxicology Research
Verified
Journal Article
Closed access
PDF file
LBLetícia Bernardini
Letícia Bernardini
EBEduardo Barbosa
Eduardo Barbosa
MCMariele Feiffer Charão
Mariele Feiffer Charão
GGGabriela Goethel
Gabriela Goethel
DMDiana Muller
Diana Muller
NBNatalia Brucker
Natalia Brucker
Formaldehyde (FA) exposure has been proven to increase the risk of asthma and cancer. This study aimed to evaluate for 28 days the FA inhalation effects on oxidative stress, inflammation process, genotoxicity, and global DNA methylation in mice as well as to investigate the potential protective effects of melatonin. For that, analyses were performed on lung, liver and kidney tissues, blood, and bone marrow. Bronchoalveolar lavage was used to measure inflammatory parameters. Lipid peroxidation (TBARS), protein carbonyl (PCO), non-protein thiols (NPSH), catalase activity (CAT), comet assay, micronuclei (MN), and global methylation were determined. The exposure to 5-ppm FA resulted in oxidative damage to the lung, presenting a significant increase in TBARS and NO levels and a decrease in NPSH levels, besides an increase in inflammatory cells recruited for bronchoalveolar lavage. Likewise, in the liver tissue, the exposure to 5-ppm FA increased TBARS and PCO levels and decreased NPSH levels. In addition, FA significantly induced DNA damage, evidenced by the increase of % tail moment and MN frequency. The pretreatment of mice exposed to FA applying melatonin improved inflammatory and oxidative damage in lung and liver tissues and attenuated MN formation in bone marrow cells. The pulmonary histological study reinforced the results observed in biochemical parameters, demonstrating the potential beneficial role of melatonin. Therefore, our results demonstrated that FA exposure with repeated doses might induce oxidative damage, inflammatory, and genotoxic effects, and melatonin minimized the toxic effects caused by FA inhalation in mice.

22 May 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
Nadine Arnold SteffensNadine Arnold Steffens
Nadine Arnold Steffens
EZEstervan Sonego Zimmermann
Estervan Sonego Zimmermann
FAFrancine Johansson Azeredo
Francine Johansson Azeredo
Rafael LindenRafael Linden
Rafael Linden
LFLuis Junior Finatto
Luis Junior Finatto
NBNatalia Brucker
Natalia Brucker
Background: Amikacin is still an essential antimicrobial to treat life-threatening infections, including multidrug-resistant microorganisms. The effectiveness of treatment has been correlated with the Cmax/MIC ratio, with a ratio of 8 being recommended, which is difficult to reach in some patients. Appropriate antibiotic exposure is important for knowing the disposition of the drug in the population. Objectives: We aimed to integrate therapeutic drug monitoring and a populational pharmacokinetic model to assess an optimal dose regimen and respective plasma exposure. Methods: Plasma levels of amikacin in peaks and troughs were determined by LC-MS/MS. The pharmacokinetic parameter was estimated to use nonlinear mixed effect modeling in Monolix® software. The probability of target attainment was also determined using the Simulx™ software. Results: A total of 39 patients were enrolled. A one-compartment model with proportional error model best described amikacin pharmacokinetic parameters, providing a Cl of 1.49 L/h and Vc of 23.18 L. The model developed could characterize the pharmacokinetic profile in Brazilian patients who underwent therapeutic drug monitoring. Conclusions: Amikacin therapeutic drug monitoring should be associated with population pharmacokinetic analysis in dose optimization and individualization, helping maintain appropriate drug exposure in special populations such as critically ill patients. This strategy may contribute to enhancing clinical outcomes.

4 January 2025 in Clinical Biochemistry
Verified
Journal Article
Closed access
Nadine Arnold SteffensNadine Arnold Steffens
Nadine Arnold Steffens
RPRodrigo Redel Petreceli
Rodrigo Redel Petreceli
VAVictor Coden Azevedo
Victor Coden Azevedo
AFAdriana Streher França
Adriana Streher França
RHRoberta Zilles Hahn
Roberta Zilles Hahn
NBNatalia Brucker
Natalia Brucker